Exploring chronic disease
9 Jan 2008
For decades, scientists working with L-form bacteria have warned that the pathogens are not killed by the purification processes used when pharmaceutical companies creates vaccines. A recent drug trial by Merck and Co., Inc. suggests that the failure of mainstream medicine to take the presence of L-form bacteria seriously has put a large group of people of people for developing a wide range of chronic diseases.
Several months ago, two international trials aimed at testing an experimental AIDS vaccine were stopped after it became clear that the vaccine did not prevent infection with the AIDS virus. The trials were conducted in the United States, Peru, Brazil, Dominican Republic, Haiti, Jamaica, Australia and South Africa. Today, the researchers conducting the trial are faced with another problem. Earlier this month they reported “worrying” indications that the thousands of people who received the vaccine are now at greater risk for infection. They have already begun counseling volunteers about the fact that they could be at higher risk for acquiring HIV – the fatal and incurable virus that causes AIDS.
To test vaccines and new drugs, researchers always aim for what are called placebo-controlled, double-blinded trials. This means that neither the researchers nor the volunteers know who gets a placebo and who gets an active ingredient – the goal being to minimize any biases in determining whether the treatment works.
But Merck and the academic researchers who conducted the vaccine trial are planning to “unblind” the study – meaning that participants will find out who got an active shot and who got a dummy injection.
“All study volunteers will be encouraged to continue to return to their study sites on a regular basis for ongoing risk reduction counseling and study-related tests,” the researchers said in a statement.
Were the vaccines contaminated with L-form bacteria? It’s quite probable. Especially since L-form bacteria are now known to create ligands that bind and block the Vitamin D Receptor (VDR). Since the VDR controls the activity of the innate immune system and the antimicrobial peptides, people who acquire L-form bacteria begin to suffer from immune dysfunction – much like the study participants in the trial described above.
Ensuring that the vaccines, injections, and blood transfusions we receive are not contaminated by L-form bacteria only strengthens the reality that the pathogens need to be brought into the spotlight immediately. In the meantime, people such as those unlucky enough to receive the actual vaccine in the Merck trial will continue to get sick after taking a measure ironically aimed at preventing disease.
Amy Proal graduated from Georgetown University in 2005 with a degree in biology. While at Georgetown, she wrote her senior thesis on Chronic Fatigue Syndrome and the Marshall Protocol.